Skip to main content
AAPL+0.69%MSFT+0.96%GOOGL+1.78%NVDA+3.63%AMZN+1.69%SPCX+1.42%TSM+2.78%AVGO+2.47%META+1.21%TSLA+1.46%LLY+0.01%WMT+0.08%JPM-0.04%BRK-B0.00%V+0.01%SKHY0.00%AMD+3.30%MU+2.48%XOM0.00%JNJ+0.15%MA-0.02%ABBV+0.08%ASMLa-9.33%COST+0.19%1398.HK+0.25%KO+0.03%CVX+0.03%0700.HK-1.26%PG+0.09%CSCO+0.07%0939.HK0.00%HD+0.05%3988.HK-1.13%BAC+0.05%1816.HK+3.45%GE-0.03%0857.HK-0.49%ORCL-0.01%UNH+0.01%1288.HK-0.45%PM+0.02%0005.HK-3.08%NVS-0.01%HSBA.L-3.62%INTC+3.30%AZN-0.01%MS+0.02%RTX+0.02%ORp-0.36%TMO+0.14%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURNZD0.00%AUDCHF0.00%EURSEK0.00%GBPUSD0.00%GBPCHF0.00%USDDKK0.00%USDHKD0.00%GBPCAD0.00%NZDCAD0.00%GBPNZD0.00%GBPAUD0.00%EURCAD0.00%EURJPY0.00%EURNOK0.00%EURUSD0.00%CADCHF0.00%CADJPY0.00%CHFJPY0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%EURPLN0.00%NZDJPY0.00%CHFNOK0.00%EURDKK0.00%NZDMXN0.00%GBPSGD0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+1.06%ETHUSD+71.01%USDTUSD+0.11%XRPUSD+61.26%SOLUSD+68.72%TRXUSDT+0.17%ZECUSDT+1.84%XMRUSDT-0.22%DOGEUSD+69.80%LINKUSD+2.59%XLMUSD-0.76%BCHUSDT-1.00%LTCUSD+68.40%UNIUSD-0.75%TONUSD+79.92%SUIUSD+1.44%HBARUSDT-0.03%TAOUSDT+2.10%AAVEUSD+1.27%ONDOUSDT+0.73%DOTUSDT+1.30%ICPUSDT+2.89%WLDUSDT+3.32%ARBUSDT+2.13%ATOMUSDT-0.50%INJUSDT+3.70%STXUSDT+2.99%PYTHUSDT+4.47%TIAUSDT+2.74%FETUSDT-0.40%SEIUSDT+0.59%JUPUSDT+2.79%GRTUSDT+0.38%OPUSDT+1.55%IOTAUSDT+1.92%POLUSDT+0.29%WIFUSDT+1.51%AXSUSDT-0.15%EOSUSDT+0.37%IMXUSDT+0.09%FARTCOINUSDT+0.82%GALAUSDT+2.69%DYDXUSDT-0.21%ORDIUSDT+2.24%NOTUSDT+1.19%RONINUSDT+1.91%AAPL+0.69%MSFT+0.96%GOOGL+1.78%NVDA+3.63%AMZN+1.69%SPCX+1.42%TSM+2.78%AVGO+2.47%META+1.21%TSLA+1.46%LLY+0.01%WMT+0.08%JPM-0.04%BRK-B0.00%V+0.01%SKHY0.00%AMD+3.30%MU+2.48%XOM0.00%JNJ+0.15%MA-0.02%ABBV+0.08%ASMLa-9.33%COST+0.19%1398.HK+0.25%KO+0.03%CVX+0.03%0700.HK-1.26%PG+0.09%CSCO+0.07%0939.HK0.00%HD+0.05%3988.HK-1.13%BAC+0.05%1816.HK+3.45%GE-0.03%0857.HK-0.49%ORCL-0.01%UNH+0.01%1288.HK-0.45%PM+0.02%0005.HK-3.08%NVS-0.01%HSBA.L-3.62%INTC+3.30%AZN-0.01%MS+0.02%RTX+0.02%ORp-0.36%TMO+0.14%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURNZD0.00%AUDCHF0.00%EURSEK0.00%GBPUSD0.00%GBPCHF0.00%USDDKK0.00%USDHKD0.00%GBPCAD0.00%NZDCAD0.00%GBPNZD0.00%GBPAUD0.00%EURCAD0.00%EURJPY0.00%EURNOK0.00%EURUSD0.00%CADCHF0.00%CADJPY0.00%CHFJPY0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%EURPLN0.00%NZDJPY0.00%CHFNOK0.00%EURDKK0.00%NZDMXN0.00%GBPSGD0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+1.06%ETHUSD+71.01%USDTUSD+0.11%XRPUSD+61.26%SOLUSD+68.72%TRXUSDT+0.17%ZECUSDT+1.84%XMRUSDT-0.22%DOGEUSD+69.80%LINKUSD+2.59%XLMUSD-0.76%BCHUSDT-1.00%LTCUSD+68.40%UNIUSD-0.75%TONUSD+79.92%SUIUSD+1.44%HBARUSDT-0.03%TAOUSDT+2.10%AAVEUSD+1.27%ONDOUSDT+0.73%DOTUSDT+1.30%ICPUSDT+2.89%WLDUSDT+3.32%ARBUSDT+2.13%ATOMUSDT-0.50%INJUSDT+3.70%STXUSDT+2.99%PYTHUSDT+4.47%TIAUSDT+2.74%FETUSDT-0.40%SEIUSDT+0.59%JUPUSDT+2.79%GRTUSDT+0.38%OPUSDT+1.55%IOTAUSDT+1.92%POLUSDT+0.29%WIFUSDT+1.51%AXSUSDT-0.15%EOSUSDT+0.37%IMXUSDT+0.09%FARTCOINUSDT+0.82%GALAUSDT+2.69%DYDXUSDT-0.21%ORDIUSDT+2.24%NOTUSDT+1.19%RONINUSDT+1.91%
AT

Akebia Therapeutics, Inc. (AKBA)

NASDAQ • Healthcare

$0.38
-$0.03 (-8.7%)
Market open

Last close at November 20, 2026 at 21:00 UTC

Open$0.41
Previous Close$0.39
Day Range$0.38 - $0.43
Avg. Volume (3M)7.1M
Market Cap$107M
52 Week Range
$0.36$1.73

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$36.9M100%
Gross Profitminus cost of goods$30.5M83%

In plain terms: out of every $100 in revenue, Akebia Therapeutics, Inc. currently loses $39.

Fundamentals & Financials

Revenue (TTM)
$197.1M
Net Income (TTM)
-$44.5M
EPS (TTM)
-$0.16
ROA (TTM)
-13.02%
Current Ratio
1.36

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-200.0%Q2 2026-$0.03
+52.4%Q3 2026-$0.02
-11.2%Q4 2026-$0.04

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Miss -11.2%

Akebia Therapeutics’ revenue missed expectations in the third fiscal quarter of 2026, with results reported November 5, 2026, as revenue of $36.9 million trailed the $46.9 million estimate (-21.4%) and fell 37% year over year from $58.8 million. Adjusted EPS was -$0.040, down from $0.002 a year ago, as the company posted a net loss of roughly $14.4 million versus net income of $540,000.00 a year earlier. Profitability remained centered in gross profit of about $30.5 million, translating to a gross margin of roughly 83%, while operating results were pressured with operating income of around -$11.5 million and an operating margin of about -31%. Despite the net loss, Akebia generated operating cash flow of about $2.3 million for the quarter. Consensus for the next period calls for EPS of -$0.040 on revenue of $48.2 million.

View full earnings history

About Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc. is a biotechnology company focused on discovering and commercializing therapies for kidney diseases. Listed on the NASDAQ Global Market under AKBA, it sells and develops treatments for chronic kidney disease complications and generated $236.2 million of revenue in FY2025.

Name
Akebia Therapeutics, Inc.
CEO
John Butler
Industry
Healthcare
Year Founded
2007
Employees
194

Today's Snapshot

AI-generated

AKBA closed 5.5% lower at 0.40, while its sector was flat. Akebia Therapeutics reported a third-quarter revenue miss, leading analysts to cut their price targets.

Trading Volume

Below 10d avg (5.9M)

4.1M

vs S&P 500 Today

Underperforming Market

-2.03%

Updated: November 20, 2026 at 21:19 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
AKBA shows a clear bearish technical profile: the stock at about $0.399 trades well below its major moving averages, including the 200-day near $1.08, which underscores broad downside positioning. Trend strength is meaningful with an ADX near 29, while momentum measures are weak—RSI sits in the low-30s and the MACD is negative—despite some very short-term oscillators flashing oversold signals. Volume-based pressure is apparent with a deeply negative OBV, and volatility is elevated with an ATR around 16% of price. Technical takeaway: Strong Sell — dominant downtrend with heavy selling and price far beneath key averages.
All signals
  • EMA (5 indicators)$0.46 - $1.05
    Sell
  • RSI (14)33.48
    Neutral
  • Stochastic %K (14, 3, 3)12.46
    Buy
  • MACD Level (12, 26)-0.09
    Sell
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.